Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

No Seismic Shifts As Torrential Rain Dampens JPM Jamboree

Drug pricing, diversity and US tax reform dominated discussions at JP Morgan. Deals announced at the conference didn't spark much excitement, but attendees were confident that the biopharma sector will still get capital market support.

BioPharmaceutical Business Strategies

PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure

Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.

Clinical Trials Cancer

Pharma Q4 Results Preview: J&J, Novartis, Celgene, Biogen & AbbVie

Novartis expected to give Joe Jimenez a good farewell gift; AbbVie says it is not planning major M&A to focus on risankizumab and upadacitinib, but Celgene is on the hunt for deals – will Juno be its next big buy?

Sales & Earnings M & A

PTAB Clears Path For Earlier Generic Zytiga Launch

Patent Trial and Appeal Board finds that the patent covering the blockbuster prostate cancer drug is unpatentable, which could allow generics to launch at-risk in October once they obtain FDA approval; at least 12 firms have pending ANDAs.

Policy Intellectual Property
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register